{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:19Z","timestamp":1777934719501,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Capecitabine, an oral fluoropyrimidine prodrug, has demonstrated promising activity in Biliary tract cancers (BTC), but its role in combination chemotherapy is still debated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of capecitabine, both alone and in combination, for treating BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      A systematic search was performed in PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar from the inception to 25\n                      <jats:sup>th<\/jats:sup>\n                      June 2024 to identify the RCTs on capecitabine therapy among BTC patients. Fixed or Random-effects model was used based on heterogeneity identified by using the I\u00b2 statistic and Cochran's Q test. Quality of the RCTs was evaluated by the modified JADAD scale and RoB-2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of six RCTs comprising 613 patients were included in the study. Pooled results showed no statistically significant differences in progression-free survival (PFS) (Mean Difference [MD]: 0.07, 95% CI: \u22121.32 to 1.46; P\u2009=\u20090.92) or overall survival (OS) (MD: \u22120.22, 95% CI: \u22121.97 to 1.53; P\u2009=\u20090.80) between capecitabine therapy and the control group. No significant differences in adverse events (AEs), including hand-foot syndrome, neutropenia, and thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Capecitabine did not demonstrate a statistically significant benefit in PFS or OS for patients with BTC. The AEs from the capecitabine combination therapy were well-tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251372874","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T05:24:01Z","timestamp":1757741041000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of capecitabine therapy in patients with Biliary tract cancer: A systematic review and meta-analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8366-0684","authenticated-orcid":false,"given":"Syed Kashif","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER) Guwahati, Kamrup, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7559-0303","authenticated-orcid":false,"given":"Christy","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER) Guwahati, Kamrup, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9778-382X","authenticated-orcid":false,"given":"Mahesh","family":"Rathod","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER) Guwahati, Kamrup, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7480-8761","authenticated-orcid":false,"given":"Krishna","family":"Undela","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER) Guwahati, Kamrup, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011746.pub2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg281"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i47.18001"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33509"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2919-0"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh096"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30915-X"},{"key":"e_1_3_3_9_2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh D-Y","unstructured":"Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVIDoa2200015. Epub ahead of print 26 July 2022.","journal-title":"NEJM Evid"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100314"},{"key":"e_1_3_3_12_2","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase three, non-inferiority trial","author":"Kim ST","unstructured":"Kim ST, Kang JH, Lee J, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase three, non-inferiority trial. Ann Oncol 2019; 30: 788-795","journal-title":"Ann Oncol"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6166"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0138-2"},{"key":"e_1_3_3_15_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021; 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_3_16_2","unstructured":"Clark HD Wells GA Huet C et al. Assessing the quality of randomized trials: reliability of the Jadad Scale."},{"key":"e_1_3_3_17_2","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne JAC","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med J 2019; 366: I4898.","journal-title":"Br Med J"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.09.018"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.51.008"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22902"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.230"},{"key":"e_1_3_3_22_2","unstructured":"Schilsky RL Bertucci D Vogelzang NJ et al. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9539-9"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/565479"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000479425"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0093"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_896_19"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000329079"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1657-1"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13599"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0270"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251372874","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251372874","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251372874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:41Z","timestamp":1777689101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251372874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":30,"alternative-id":["10.1177\/10781552251372874"],"URL":"https:\/\/doi.org\/10.1177\/10781552251372874","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"10781552251372874"}}